A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis
- PMID: 23855653
- PMCID: PMC3722100
- DOI: 10.1186/1479-5876-11-171
A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis
Abstract
Introduction: Regenerative medicine and particular adult stem cells represent an alternative option with several fruitful therapeutic applications in patients suffering from chronic lung diseases including idiopathic pulmonary fibrosis (IPF). Nevertheless, lack of knowledge regarding the origin and the potential of mesenchymal stem cells (MSCs) to differentiate into fibroblasts has limited their use for the treatment of this dismal disease.
Patients and methods: To this end, we conducted a phase Ib, non-randomized, clinical trial to study the safety of three endobronchial infusions of autologous adipose derived stromal cells (ADSCs)-stromal vascular fraction (SVF) (0.5 million cells per kgr of body weight per infusion) in patients with IPF (n=14) of mild to moderate disease severity (forced vital capacity -FVC>50% predicted value and diffusion lung capacity for carbon monoxide-DLCO>35% of predicted value). Our primary end-point was incidence of treatment emergent adverse events within 12 months. Alterations of functional, exercise capacity and quality of life parameters at serial time points (baseline, 6 and 12 months after first infusion) were exploratory secondary end-points.
Results: No cases of serious or clinically meaningful adverse events including short-term infusional toxicities as well as long-term ectopic tissue formation were recorded in all patients. Detailed safety monitoring through several time-points indicated that cell-treated patients did not deteriorate in both functional parameters and indicators of quality of life.
Conclusions: The clinical trial met its primary objective demonstrating an acceptable safety profile of endobronchially administered autologous ADSCs-SVF. Our findings accelerate the rapidly expanded scientific knowledge and indicate a way towards future efficacy trials.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3722100/bin/1479-5876-11-171-1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3722100/bin/1479-5876-11-171-2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3722100/bin/1479-5876-11-171-3.gif)
Similar articles
-
Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.J Transl Med. 2011 Oct 21;9:182. doi: 10.1186/1479-5876-9-182. J Transl Med. 2011. PMID: 22017817 Free PMC article.
-
Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.Clin Respir J. 2018 Jun;12(6):2084-2089. doi: 10.1111/crj.12777. Epub 2018 Mar 12. Clin Respir J. 2018. PMID: 29412521 Clinical Trial.
-
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.Chest. 2017 May;151(5):971-981. doi: 10.1016/j.chest.2016.10.061. Epub 2016 Nov 24. Chest. 2017. PMID: 27890713 Free PMC article. Clinical Trial.
-
Adipose-Derived Stromal Vascular Fraction Cells: Update on Clinical Utility and Efficacy.Crit Rev Eukaryot Gene Expr. 2015;25(2):145-52. doi: 10.1615/critreveukaryotgeneexpr.2015013057. Crit Rev Eukaryot Gene Expr. 2015. PMID: 26080608 Review.
-
Stromal vascular fraction: A regenerative reality? Part 2: Mechanisms of regenerative action.J Plast Reconstr Aesthet Surg. 2016 Feb;69(2):180-8. doi: 10.1016/j.bjps.2015.10.014. Epub 2015 Oct 24. J Plast Reconstr Aesthet Surg. 2016. PMID: 26546112 Review.
Cited by
-
Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic.Am J Stem Cells. 2024 Apr 25;13(2):37-58. doi: 10.62347/JAWM2040. eCollection 2024. Am J Stem Cells. 2024. PMID: 38765802 Free PMC article. Review.
-
The Plastic Interplay between Lung Regeneration Phenomena and Fibrotic Evolution: Current Challenges and Novel Therapeutic Perspectives.Int J Mol Sci. 2023 Dec 31;25(1):547. doi: 10.3390/ijms25010547. Int J Mol Sci. 2023. PMID: 38203718 Free PMC article. Review.
-
Emerging delivery approaches for targeted pulmonary fibrosis treatment.Adv Drug Deliv Rev. 2024 Jan;204:115147. doi: 10.1016/j.addr.2023.115147. Epub 2023 Dec 6. Adv Drug Deliv Rev. 2024. PMID: 38065244 Free PMC article. Review.
-
Boosting therapeutic efficacy of mesenchymal stem cells in pulmonary fibrosis: The role of genetic modification and preconditioning strategies.Iran J Basic Med Sci. 2023;26(9):1001-1015. doi: 10.22038/IJBMS.2023.69023.15049. Iran J Basic Med Sci. 2023. PMID: 37605719 Free PMC article. Review.
-
Mesenchymal stem cells and pulmonary fibrosis: a bibliometric and visualization analysis of literature published between 2002 and 2021.Front Pharmacol. 2023 Jul 4;14:1136761. doi: 10.3389/fphar.2023.1136761. eCollection 2023. Front Pharmacol. 2023. PMID: 37469875 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous